Brought to you by 
Series B brings in CHF44mm for Evolva
15 Dec 2009
Executive Summary
Evolva Biotech SA (developing compounds for renal, metabolic, cardiovascular, and infectious diseases) has raised CHF44mm ($42.7mm) with the closing of its Series B venture round. Current backer Aravis led and was joined by fellow shareholders BioMedInvest, Astellas Venture, Dansk Innovation, Novartis BioVenture Fund, Vinci Capital, and Sunstone Capital. New investors Entrepreneurs Fund, Auriga Partners, Vinci Capital & Renaissance PME, and Wellington Partners also participated. Evolva will use the funds for its merger with fellow Swiss biotech Arpida.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B brings in CHF44mm for Evolva
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice